Jeffrey Frankel
Burien, WANPI 1487694154
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $267,832 of the $393,410 with a category attached, or 68.1%. 33 manufacturers reported payments, led by Sumitomo Pharma America, Inc. at 53.3% of the total. Reporting peaked in 2023 at $119,360 and has fallen 57.2% since, to $51,063 in 2025.
Across 480 payments — averaging $819.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$210K
- Myovant Sciences Inc.$65K
- Astellas Pharma US Inc$56K
- Pfizer$25K
- Tolmar Pharmaceuticals, Inc.$17K
- Urovant Sciences Inc$10K
- plus $10K from 27 others
Across 70 payments — averaging $1731.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$46K
- Ferring Pharmaceuticals AS$29K
- Janssen Research & Development, LLC$22K
- Ferring International Pharmascience Center US$16K
- Sumitomo Pharma America, Inc.$5K
- Urovant Sciences Inc$3K
What the payments were for
- Consulting fees$73,03819%
- Speaking & faculty fees$267,83268%
- Travel & lodging$40,25210%
- Food & beverage$11,6203%
- Education$6350%
- Entertainment$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 160 | $209,833 |
| Myovant Sciences Inc. | 46 | $65,357 |
| Astellas Pharma US Inc | 76 | $55,745 |
| Pfizer | 37 | $25,207 |
| Tolmar Pharmaceuticals, Inc. | 10 | $17,407 |
| Urovant Sciences Inc | 15 | $9,575 |
| AstraZeneca | 6 | $3,443 |
| Myovant Sciences GmbH | 8 | $1,531 |
| Janssen Scientific Affairs, LLC | 5 | $834 |
| Dendreon Pharmaceuticals LLC | 14 | $477 |
| Ferring Pharmaceuticals Inc. | 13 | $451 |
| Johnson & Johnson | 15 | $407 |
| Verathon Inc. | 1 | $400 |
| AbbVie | 13 | $355 |
| Progenics Pharmaceuticals, Inc. | 4 | $354 |
| Amgen | 7 | $255 |
| Bayer | 9 | $244 |
| Boston Scientific | 3 | $193 |
| Teleflex LLC | 3 | $176 |
| Immunitybio, Inc. | 1 | $162 |
| Coloplast | 7 | $161 |
| Astellas Pharma Inc | 1 | $141 |
| Convatec Inc. | 4 | $118 |
| 180 Medical, Inc. | 3 | $97 |
| Myriad Genetic Laboratories, Inc. | 5 | $95 |
| Dentsply IH Inc. | 4 | $88 |
| Merck | 1 | $87 |
| Rochester Medical Corporation | 3 | $58 |
| Astellas Pharma Global Development | 2 | $47 |
| Axonics, Inc. | 1 | $35 |
| Verity Pharmaceuticals Inc. | 1 | $34 |
| Urogen Pharma, Inc. | 1 | $25 |
| Laborie Medical Technologies Corp. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORGOVYX$172,991
- GEMTESA$104,969
- XTANDI$39,392
- MYRBETRIQ$23,538
- ELIGARD$17,252
- LYNPARZA$3,381
- TALZENNA$2,160
- Erleada$872
- NPD Clinical Study$400
- FIRMAGON$229
- ANKTIVA$162
- PYLARIFY$131
- UroLift System$124
- Lupron Depot$113
- GENERAL ERECTILE DYSFUNCTION$112
- PROVENGE$111
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.